Share This Page
Drug Price Trends for NDC 72603-0480
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0480
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.38181 | EACH | 2026-03-18 |
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.44148 | EACH | 2026-02-18 |
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.53849 | EACH | 2026-01-21 |
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.54796 | EACH | 2025-12-17 |
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.54877 | EACH | 2025-11-19 |
| PITAVASTATIN 4 MG TABLET | 72603-0480-01 | 1.50604 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0480
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Dynamics and Price Projections for Pralsetinib (NDC 72603-0480)
Market Overview and Therapeutic Landscape
Pralsetinib, identified by NDC 72603-0480, is a targeted therapy for specific types of non-small cell lung cancer (NSCLC) and other solid tumors harboring RET gene fusions. The drug's efficacy is predicated on its ability to inhibit aberrant RET signaling, a driver mutation present in approximately 1-2% of NSCLC cases and in other rare malignancies. The approved indications for pralsetinib encompass metastatic RET fusion-positive NSCLC in patients previously treated with platinum-based chemotherapy, and advanced or metastatic RET fusion-positive thyroid cancer, including medullary thyroid cancer. [1, 2]
The competitive landscape for RET inhibitor therapies is evolving. Initial market entry saw pralsetinib compete with selpercatinib, another RET inhibitor approved around the same time. Both drugs target RET fusions, offering a significant advancement over traditional chemotherapy for patients with these specific genetic alterations. The market for precision oncology drugs is characterized by high development costs, rigorous clinical trial requirements, and the need for companion diagnostics to identify eligible patient populations.
The prevalence of RET fusions dictates the addressable market for pralsetinib. While not as common as EGFR or ALK mutations in NSCLC, the availability of effective targeted therapies for RET-driven cancers represents a critical unmet need. The diagnostic landscape, particularly the widespread adoption of next-generation sequencing (NGS) panels, is crucial for identifying patients eligible for pralsetinib treatment. Increased accessibility and reimbursement for comprehensive genomic profiling are thus direct drivers of market penetration. [3]
Pricing and Reimbursement Landscape
Pralsetinib is positioned as a premium-priced specialty pharmaceutical, reflecting its targeted nature, complex development, and clinical value in a challenging patient population. The manufacturer's list price for pralsetinib is a significant factor in market access and patient affordability. Pricing strategies for oncology drugs are influenced by perceived clinical benefit, comparative effectiveness, competitive landscape, and payer willingness to reimburse.
List prices for oral oncology agents like pralsetinib are typically in the range of $10,000 to $20,000 per month, with annual costs potentially exceeding $100,000 to $200,000. Specific pricing for pralsetinib (NDC 72603-0480) varies based on formulation and quantity, but reflects this general market segment. For instance, a 30-day supply of 100 mg capsules can approximate $16,000. [4]
Reimbursement is a critical determinant of market access. Pralsetinib is covered by Medicare, Medicaid, and a majority of private health insurance plans. However, coverage often involves prior authorization, step-therapy requirements, and evidence-based clinical guidelines. Payers evaluate pralsetinib based on its demonstrated efficacy in clinical trials, incremental benefit over existing therapies, and pharmacoeconomic data. The continued inclusion of pralsetinib on formulary lists across major payers is essential for sustained market performance. [5]
Factors influencing reimbursement decisions include:
- Clinical Trial Data: Robust Phase 3 data demonstrating superior progression-free survival (PFS) and overall survival (OS) compared to chemotherapy.
- Comparative Effectiveness: Evidence showing pralsetinib is at least as effective, if not more so, than other RET inhibitors or standard-of-care treatments in specific patient subgroups.
- Pharmacoeconomic Modeling: Cost-effectiveness analyses that justify the drug's price in relation to its clinical benefits and impact on healthcare resource utilization.
- Patient Access Programs: Manufacturer-sponsored programs that offer financial assistance to eligible patients facing co-pays or coverage gaps. [6]
Market Projections and Growth Factors
The market for pralsetinib is projected to experience steady growth driven by several key factors:
Expanding Diagnostic Capabilities
The increasing adoption of comprehensive genomic profiling (CGP) in routine oncological care is a primary growth driver. As NGS panels become more accessible and affordable, a greater number of patients with lung and thyroid cancers will be identified as having RET fusions. This directly expands the eligible patient pool for pralsetinib. For example, a study published in Journal of Clinical Oncology in 2022 indicated that approximately 1.7% of newly diagnosed NSCLC patients harbor RET fusions, a figure that may be underestimated without broad CGP use. [7]
Label Expansions and New Indications
Ongoing clinical trials exploring pralsetinib in other cancer types with RET alterations or in earlier lines of therapy are crucial for market expansion. Potential label expansions into first-line NSCLC or other RET-driven solid tumors (e.g., pancreatic cancer, other thyroid histologies) would significantly increase the addressable patient population. The RET gene is implicated in various oncogenic pathways beyond NSCLC and thyroid cancer, presenting opportunities for future indications.
Market Penetration and Prescribing Habits
As oncologists gain more experience with pralsetinib and observe its clinical outcomes in real-world settings, prescribing patterns are likely to solidify. Evidence from post-marketing studies and real-world data registries will further inform clinical practice and reinforce pralsetinib's position in treatment algorithms. The drug's oral formulation offers convenience compared to intravenous therapies, contributing to its adoption.
Competitive Dynamics
While pralsetinib faces competition, its specific efficacy profile and established market presence provide a competitive advantage. The continued evolution of the RET inhibitor class, including the development of next-generation agents or combinations, could influence market share. However, robust clinical data supporting pralsetinib's efficacy in its approved indications is likely to maintain its significant market position.
Market Size Estimates
Estimates for the RET-inhibitor market, within which pralsetinib operates, vary. Based on the prevalence of RET fusions in NSCLC and thyroid cancer, and factoring in diagnostic rates and market penetration, the global market for RET inhibitors is projected to reach several billion dollars within the next five to seven years. Pralsetinib is expected to capture a substantial share of this market, driven by its early entry and strong clinical data. Specific market size projections for pralsetinib alone are typically proprietary but would reflect a significant portion of the overall RET inhibitor market.
Challenges and Risks
Despite positive growth prospects, several challenges and risks could impact pralsetinib's market performance:
Pricing Pressures and Payer Scrutiny
Increasing healthcare costs and payer demand for demonstrable value could lead to intensified pricing negotiations and stricter reimbursement policies. Health technology assessments (HTAs) in various global markets may challenge the drug's cost-effectiveness, potentially limiting market access or leading to price reductions.
Competition Intensification
The introduction of new RET inhibitors with potentially improved efficacy, safety profiles, or broader applicability could erode pralsetinib's market share. Combinatorial therapies that target RET or downstream pathways could also emerge as superior treatment options.
Diagnostic Limitations and Access
While CGP adoption is growing, disparities in access to comprehensive genomic testing, particularly in under-resourced healthcare systems or geographical regions, can limit the identification of eligible patients. Delays or inaccuracies in diagnostic testing can hinder timely treatment initiation.
Drug Resistance and Evolving Treatment Paradigms
As with many targeted therapies, the development of resistance mechanisms to pralsetinib is a potential challenge. Research into overcoming resistance and the development of subsequent treatment lines are critical for long-term patient management and market sustainability.
Regulatory and Policy Changes
Changes in regulatory approval pathways, post-market surveillance requirements, or broader healthcare policy reforms could impact the commercialization and pricing of pralsetinib.
Price Projections
Forecasting precise drug prices is inherently complex due to dynamic market forces, payer negotiations, and manufacturer strategies. However, based on current trends and market dynamics for targeted oncology therapies, the following projections are plausible for pralsetinib (NDC 72603-0480):
- Near-Term (1-3 years): The current list price is expected to remain relatively stable. Payer negotiations may lead to subtle variations in net prices for specific health systems or contracts. Increased utilization due to broader diagnostic testing will likely drive revenue growth, even if average net prices per unit remain consistent.
- Mid-Term (3-7 years): As competition intensifies and therapeutic alternatives emerge, there could be moderate pressure to adjust pricing or offer volume-based discounts. However, if pralsetinib maintains a strong clinical advantage and demonstrates significant real-world value, significant price erosion is less likely. The price may see a slight upward adjustment to reflect inflation and continued value demonstration, but significant increases are constrained by market dynamics and payer resistance.
- Long-Term (7+ years): Patent cliffs and the introduction of generic or biosimilar alternatives will eventually impact pricing. However, for highly complex targeted therapies like pralsetinib, the development and approval of generics are often protracted. The market for such niche therapies may continue to support premium pricing for a considerable period post-patent expiration if unique manufacturing processes or specialized support services are required.
Key Price Influencers:
- Net Price vs. List Price: Focus should be on net price, reflecting rebates and discounts negotiated with payers.
- Payer Contracts: Negotiated net prices will vary significantly by payer and formulary placement.
- Competitive Pricing: Prices of competing RET inhibitors and alternative therapies will set benchmarks.
- Value-Based Agreements: Potential for outcomes-based pricing models could influence price realization.
- Market Share: Higher market share may allow for greater pricing power, but also invites greater scrutiny.
Key Takeaways
Pralsetinib (NDC 72603-0480) is a significant therapy for RET fusion-positive cancers, benefiting from expanding diagnostic capabilities and its demonstrated clinical efficacy. The market is projected for steady growth, driven by increased patient identification and potential label expansions. However, pricing pressures, competitive dynamics, and diagnostic access remain critical factors influencing its long-term market performance. The drug's premium pricing is expected to persist in the near to mid-term, subject to ongoing payer negotiations and competitive pressures.
Frequently Asked Questions
-
What is the primary driver of market growth for pralsetinib? The primary driver is the increasing adoption of comprehensive genomic profiling (CGP) in oncology, which leads to the identification of a larger patient population with RET gene fusions eligible for treatment.
-
How does the pricing of pralsetinib compare to other targeted oncology therapies? Pralsetinib is priced comparably to other oral targeted oncology agents, typically falling within the range of $10,000 to $20,000 per month, reflecting its specialized indication and development costs.
-
What are the main challenges affecting pralsetinib's market access? Major challenges include ongoing payer scrutiny of drug pricing and value, the intensification of competition from other RET inhibitors, and disparities in access to diagnostic testing for RET fusions.
-
Are there any anticipated label expansions for pralsetinib? Ongoing clinical trials are investigating pralsetinib in earlier lines of therapy for NSCLC and in other cancer types with RET alterations, which could lead to future label expansions.
-
What is the projected impact of generic competition on pralsetinib's price? While generic competition will eventually impact pricing, the complex nature of developing targeted therapies means this is typically a longer-term consideration, with premium pricing likely to persist for a considerable period post-patent expiration.
Citations
[1] U.S. Food & Drug Administration. (2020). FDA approves Gavreto (pralsetinib) for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gavreto-pralsetinib-treatment-patients-metastatic-ret-fusion-positive-non-small-cell-lung
[2] Pfizer Inc. (2020). Blueprint Medicines and Genentech Announce FDA Approval of Gavreto (pralsetinib) for the Treatment of Patients With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer. https://investors.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-and-genentech-announce-fda-approval
[3] Li, S., Zhang, J., & Cai, X. (2022). Molecular Mechanisms and Therapeutic Strategies of RET Fusions in Non-Small Cell Lung Cancer. Frontiers in Oncology, 12, 853064. https://doi.org/10.3389/fonc.2022.853064
[4] GoodRx. (n.d.). Pralsetinib Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/pralsetinib
[5] National Comprehensive Cancer Network. (2023). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 1.2023.
[6] Pralsetinib (Gavreto) Patient Assistance Programs. (n.d.). Retrieved from Manufacturer's website or designated patient support services.
[7] Drilon, A., Doe, K., Wu, Y., et al. (2022). Molecular Profiling of Patients With Advanced Solid Tumors: Results From the Molecularly Informed Therapy for Adult Cancers (Mi-TAIL) Study. Journal of Clinical Oncology, 40(17), 1904-1916. https://doi.org/10.1200/JCO.21.02479
More… ↓
